|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-7-28
|
|
pubmed:abstractText |
Post-transplant lymphoproliferative disorder (PTLD) is often associated with Epstein-Barr virus (EBV). However, in this report, we describe a heart transplant recipient with pathologically proven EBV-positive PTLD with undetectable virus by polymerase chain reaction. The patient had remission after anti-CD20 antibody treatment early after transplantation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1557-3117
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
928-31
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18656811-Adolescent,
pubmed-meshheading:18656811-Antibodies,
pubmed-meshheading:18656811-Antibodies, Monoclonal,
pubmed-meshheading:18656811-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18656811-Antigens, CD20,
pubmed-meshheading:18656811-Epstein-Barr Virus Infections,
pubmed-meshheading:18656811-Heart Transplantation,
pubmed-meshheading:18656811-Herpesvirus 4, Human,
pubmed-meshheading:18656811-Humans,
pubmed-meshheading:18656811-Immunologic Factors,
pubmed-meshheading:18656811-Lymphoproliferative Disorders,
pubmed-meshheading:18656811-Male,
pubmed-meshheading:18656811-Polymerase Chain Reaction,
pubmed-meshheading:18656811-Treatment Outcome,
pubmed-meshheading:18656811-Viral Load
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
|
|
pubmed:affiliation |
Institut de Cardiologie de Québec, Hôpital Laval, Sainte-Foy, Québec, Canada.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
